Analysis of CD8 T-cell Response by IFNgamma ELISPOT and H-2L(d)/pRL1a Tetramer Assays in PRL1a Multiple Antigen Peptide-immunized and RL Male 1-bearing BALB/c and (BALB/c X C57BL/6) F(1) Mice

Overview

Journal Cancer Sci

Specialty Oncology

Date 2004 Mar 16

PMID 15016326

Authors

Itsuro Takada

Yuji Noguchi

Akira Kenjo

Hisashi Wada

Akiko Uenaka

Teizo Fujita

Hajime Inoue

Eiichi Nakayama

Affiliations

Soon will be listed here.

Abstract

We previously identified an H-2L(d)-binding peptide pRL1a (IPGLPLSL) on RL male 1 that is predominantly recognized by cytotoxic T-lymphocytes (CTLs). MAP is a multibranched lysine core with antigenic peptides. Immunization of BALB/c mice with pRL1a MAP effectively induced pRL1a CTLs. Here, we demonstrate the presence of pRL1a-recognizing CD8(+) T-cells in pRL1a MAP-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6)F(1) mice by using IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays. A few IFNgamma ELISPOTs and no tetramer-positive cells were detected ex vivo in spleen cells from BALB/c mice immunized with pRL1a MAP. After a single in vitro stimulation with RL male 1, 432 and 741 IFNgamma ELISPOTs/10(5) cells were detected and tetramer-positive CD8(+) T-cells occurred at relative frequencies of 5.7% and 30.8% in splenic CD8(+) T-cells from mice that had been doubly and triply immunized, respectively, against pRL1a MAP. Tetramer-positive cells displayed two distinct cell populations, CD62L(low) and CD62L(high). Secondary in vitro stimulation expanded CD62L(high) cells more efficiently than CD62L(low) cells. Furthermore, a higher frequency of IFNgamma-producing and tetramer-positive CD8(+) T-cells was detected ex vivo in RL male 1-bearing semi-allogeneic (BALB/c x C57BL/6)F(1) than in BALB/c mice on day 14 after tumor inoculation.

References

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

Huang W, Nardelli B, Tam J . Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol Immunol. 1994; 31(15):1191-9. DOI: 10.1016/0161-5890(94)90033-7. View

Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E . Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med. 1994; 180(5):1599-607. PMC: 2191716. DOI: 10.1084/jem.180.5.1599. View

Tan L, Gudgeon N, Annels N, Hansasuta P, OCallaghan C, Rowland-Jones S . A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999; 162(3):1827-35. View

Wang C, Looney D, Li M, Walfield A, Ye J, Hosein B . Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science. 1991; 254(5029):285-8. DOI: 10.1126/science.254.5029.285. View

Chai S, Clavijo P, Tam J, Zavala F . Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J Immunol. 1992; 149(7):2385-90. View

Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P . Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A. 2001; 98(18):10302-7. PMC: 56956. DOI: 10.1073/pnas.181348898. View

Altman J, Suresh M, Sourdive D, Zajac A, Miller J, Slansky J . Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998; 8(2):177-87. DOI: 10.1016/s1074-7613(00)80470-7. View

Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M . An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune.... J Exp Med. 1999; 190(5):651-67. PMC: 2195616. DOI: 10.1084/jem.190.5.651. View

10.

Lee P, Yee C, Savage P, Fong L, Brockstedt D, Weber J . Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; 5(6):677-85. DOI: 10.1038/9525. View

11.

Nakayama E, Shiku H, Takahashi T, Oettgen H, Old L . Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1979; 76(7):3486-90. PMC: 383851. DOI: 10.1073/pnas.76.7.3486. View

12.

Reignat S, Webster G, Brown D, Ogg G, King A, Seneviratne S . Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002; 195(9):1089-101. PMC: 2193712. DOI: 10.1084/jem.20011723. View

13.

Reinhardt R, Khoruts A, Merica R, ZELL T, Jenkins M . Visualizing the generation of memory CD4 T cells in the whole body. Nature. 2001; 410(6824):101-5. DOI: 10.1038/35065111. View

14.

Appay V, Nixon D, Donahoe S, Gillespie G, Dong T, King A . HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000; 192(1):63-75. PMC: 1887711. DOI: 10.1084/jem.192.1.63. View

15.

Coulie P, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M . A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A. 2001; 98(18):10290-5. PMC: 56954. DOI: 10.1073/pnas.161260098. View

16.

Kuroda M, Schmitz J, Charini W, Nickerson C, Lord C, Forman M . Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys. J Virol. 1999; 73(2):1573-9. PMC: 103982. DOI: 10.1128/JVI.73.2.1573-1579.1999. View

17.

Valmori D, Pittet M, Rimoldi D, Lienard D, Dunbar R, Cerundolo V . An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 1999; 59(9):2167-73. View

18.

Manki A, Ono T, Uenaka A, Seino Y, Nakayama E . Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res. 1998; 58(9):1960-4. View

19.

Nardelli B, Tam J . Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology. 1993; 79(3):355-61. PMC: 1421990. View

20.

Nakayama E, Uenaka A . Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med. 1985; 161(2):345-55. PMC: 2187571. DOI: 10.1084/jem.161.2.345. View